Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes
Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.
You may also be interested in...
Lundbeck executive calls for adaptive trial designs, transdiagnostic approach, and more scientific discussions between sponsors and the US Food and Drug Administration.
Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.
Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.